Liquid Biopsy is a procedure of sampling and analyzing non-solid biological tissues, for the screening of cancer and other inflammatory conditions, associated with cardiac and other medical disorders. The sampling procedures are minimally invasive, quick and incur minimal patient pain and risk. Liquid Biopsy also helps in the early diagnosis of various types of cancers such as breast cancer, non-small cell lung carcinoma, lymphomas, head and neck cancer, and leukemia.
Advent of Advanced Healthcare Technologies Fuels the Global Liquid Biopsy Market
Liquid biopsy is an emerging technology and has the potential to revolutionize early cancer detection by analyzing available ctDNA for specific mutation profiles, fragmentation patterns, and methylation signatures. The significant developments in a digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies has led to a significant reduction in sequencing cost with the improvement in the accuracy of liquid biopsy. Further advancements in technology are expected to trigger the growth of the liquid biopsy market in the upcoming years.
Adoption of Circulating Biomarkers for Early Detection and Screening of Cancer
Currently, circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are the mostly used liquid biopsy-derived biomarkers. In recent years, CTCs have gained immense significance in detecting tumors, replacing invasive tissue biopsies not only due to their ease in sampling but also in providing data regarding tumor conditions in a â€˜real-timeâ€™ manner. CTCs can also be used in vivo for the generation of patient-derived tumor models that assist in treatments.
Upcoming Market Challenges: Global Liquid Biopsy Market
Some of the upcoming challenges restricting the growth of the liquid biopsy market are stringent government regulations, suboptimal patient adherence, low sensitivity for early-stage disease, and high false-positive rates. The wrong diagnosis can lead to false-negative results which can impact the informative value of the liquid biopsy tests for cancer.
Regional Analysis: North America Leads the Adoption of Liquid Biopsy Market
From a geographical perspective, North America holds the largest share of the liquid biopsy market. Rising prevalence of cancer cases among the US population, adoption of liquid biopsy for cancer diagnosis, patient preference for non-invasive diagnosis and monitoring and the presence of key players in this region are some of the key factors driving the market growth.
Competitive Landscape Analysis: Global Liquid Biopsy Market
Some of the leading players operating in the global liquid biopsy market are F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Guardant Health Inc., MDxHealth SA, and Illumina Inc., among others.
Explore Detailed Research Report on Liquid Biopsy Market @ https://meditechinsights.com/liquid-biopsy-market/